Direct sodium removal method, solution and apparatus to reduce fluid overload in heart failure patients
US10898631B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 21, 2018 |
| Grant date | Jan 26, 2021 |
| Priority date | — |
| Expiry date | May 21, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2210/1085
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.